

**Spain Biochip Market By Technology (Microarray, Microfluidics), By Type (DNA Chips, Lab-On-a-Chips, Protein Chips, Others), By Application (Drug Discovery & Development, Disease Diagnostics, Genomics, Proteomics, Others), By End User (Hospitals & Diagnostics Centers, Academic & Research Institutes, Biotechnology & Pharmaceutical Companies, Others), By Region, Competition Forecast & Opportunities, 2019-2029F**

Market Report | 2024-12-13 | 85 pages | TechSci Research

**AVAILABLE LICENSES:**

- Single User License \$3500.00
- Multi-User License \$4500.00
- Custom Research License \$7000.00

**Report description:**

Spain Biochip Market was valued at USD 288.58 Million in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 13.01% through 2029. The Spain Biochip Market has witnessed notable growth in recent years, driven by advancements in biotechnology and a rising emphasis on personalized medicine. Biochips, microarray-based devices facilitating the simultaneous analysis of multiple biological elements, have found diverse applications in genomics, proteomics, and diagnostics.

**Key Market Drivers**

**Technological Advancements**

In the realm of biomedical technology, Spain's Biochip Market is experiencing a transformative wave driven by technological advancements. The continuous evolution of biochip technologies is not only reshaping the landscape of diagnostics but also propelling the market to new heights. Technological strides have significantly improved the sensitivity and specificity of biochips, making them more precise and reliable. This heightened accuracy is a game-changer in diagnostics, enabling the detection of minute quantities of biological markers. Whether it's identifying genetic variations or pinpointing specific proteins, the enhanced sensitivity of modern biochips is expanding the scope of applications in genomics and proteomics research.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Advancements in microfabrication and nanotechnology have led to the miniaturization of biochips, allowing for the integration of multiple functionalities into compact devices. This miniaturization, coupled with multiplexing capabilities, enables the simultaneous analysis of numerous biological elements on a single platform. As a result, researchers and clinicians can conduct comprehensive analyses with minimal sample volumes, promoting efficiency and cost-effectiveness. The convergence of biochip technology with big data analytics and artificial intelligence (AI) is a key driver of growth. The integration of these technologies enables the efficient analysis and interpretation of large datasets generated by biochips. AI algorithms enhance the accuracy of data interpretation, aiding in the identification of complex patterns and correlations within biological data. This synergy opens new avenues for personalized medicine and data-driven decision-making in healthcare.

Technological advancements are facilitating the development of biochips for point-of-care applications, bringing diagnostics closer to the patient. Miniatured, portable biochip devices allow for rapid on-site analysis, reducing turnaround times for critical results. This is particularly significant in emergency situations and resource-limited settings, where timely and accurate diagnostics can make a substantial impact on patient outcomes. Integration with next-generation sequencing (NGS) technologies is further elevating the capabilities of biochips. This convergence allows for a more comprehensive analysis of genetic material, offering insights into complex genomic variations. The synergy between biochips and NGS is driving advancements in precision medicine, facilitating tailored treatment approaches based on an individual's unique genetic profile.

#### Proliferation of Personalized Medicine

Spain's Biochip Market is witnessing a transformative wave propelled by the rising tide of personalized medicine. As the healthcare landscape shifts towards tailored and individualized treatment approaches, biochips are emerging as pivotal tools in this paradigm shift. Personalized medicine, often synonymous with precision medicine, emphasizes tailoring medical treatments to the individual characteristics of each patient. Biochips play a crucial role in this landscape by providing a platform for the rapid and comprehensive analysis of genetic material. The ability to scrutinize an individual's genetic makeup enables healthcare professionals to make informed decisions about treatment strategies, predicting responses to specific medications and identifying potential risks.

Biochips excel in the simultaneous analysis of multiple biological elements, making them invaluable in identifying biomarkers associated with various diseases. In the context of personalized medicine, biochips aid in the early detection and monitoring of conditions based on specific biomarkers. Whether it's cancer, cardiovascular diseases, or genetic disorders, biochips contribute to a more nuanced understanding of an individual's health status, facilitating timely interventions.

The integration of biochips with personalized medicine enhances diagnostic capabilities. These microarray-based devices allow for the swift and accurate detection of genetic variations and protein markers associated with diseases. In personalized medicine, early and precise diagnosis is paramount, and biochips are at the forefront of enabling such capabilities. This, in turn, fosters a proactive approach to disease management and monitoring. The insights derived from biochip analyses empower healthcare providers to design targeted and effective therapeutic interventions. By understanding the unique genetic makeup of patients, personalized medicine aims to match treatments with the specific characteristics of each individual. Biochips contribute to the identification of therapeutic targets and the monitoring of treatment responses, paving the way for more effective and personalized therapeutic regimens.

#### Increasing Healthcare Expenditure

Spain's Biochip Market is on an upward trajectory, fueled in part by a significant factor: the escalating investment in healthcare. As the country channels more resources into advancing its healthcare infrastructure and research capabilities, the biochip market is emerging as a key beneficiary.

A substantial portion of increased healthcare expenditure is directed towards research and development initiatives. In Spain, this translates into a robust environment for biomedical research, with a particular focus on innovative technologies like biochips. The infusion of funds into R&D accelerates the pace of biochip technology development, fostering the creation of more advanced, efficient, and specialized biochip applications. With higher healthcare expenditure, there is a greater willingness and capacity to adopt advanced technologies. Biochips, being at the forefront of biomedical technology, are well-positioned to benefit from this trend. The funds allocated to healthcare infrastructure and technology acquisition contribute to the widespread adoption of biochips in diagnostic laboratories, research institutions, and healthcare facilities across Spain.

Increased investment in healthcare often translates to the expansion and modernization of healthcare facilities. The integration of

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

biochip technology into these upgraded facilities enhances their diagnostic capabilities. Biochips, with their multiplexing and high-throughput capabilities, align with the evolving needs of modern healthcare, offering rapid and comprehensive analyses that contribute to more accurate and timely diagnoses. The growing healthcare expenditure fosters collaboration between industry players and research institutions. This collaboration is instrumental in translating cutting-edge research into practical applications, propelling the development and commercialization of biochip technologies. The synergy between academia and industry accelerates the pace of innovation, bringing new and improved biochip products to the market.

Precision medicine, which tailors medical treatment to individual characteristics, is gaining prominence globally. Increased healthcare spending enables Spain to embrace and invest in precision medicine initiatives. Biochips play a pivotal role in this context by providing the necessary tools for analyzing genetic and molecular information. As precision medicine becomes more integral to healthcare strategies, the demand for biochips is likely to grow.

#### Applications in Disease Diagnostics

In the dynamic landscape of healthcare, Spain's Biochip Market is experiencing a surge in growth, driven significantly by the expanding applications in disease diagnostics. Biochips, with their multifaceted capabilities, have become indispensable tools in the realm of diagnostics. One of the key strengths of biochips lies in their ability to conduct rapid and simultaneous analyses of multiple biological elements. In disease diagnostics, this feature is revolutionary. Biochips enable healthcare professionals to swiftly examine a range of biomarkers, providing a comprehensive overview of an individual's health status in a time-efficient manner. The speed and efficiency of biochip-based diagnostics contributes to timely interventions and improved patient outcomes.

Biochips play a pivotal role in the early detection of diseases, ranging from infectious diseases to genetic disorders. The simultaneous analysis of diverse biomarkers allows for the identification of subtle changes in the biological profile, often before symptoms manifest. Early detection is a cornerstone in the effective management of diseases, and biochips are at the forefront of enabling proactive healthcare strategies through timely diagnosis. The applications of biochips extend beyond traditional diagnostics to support the paradigm of personalized medicine. By analyzing an individual's genetic makeup and identifying specific biomarkers associated with diseases, biochips facilitate the tailoring of treatment approaches. This, in turn, contributes to the realization of targeted therapies, where interventions are designed based on the unique characteristics of each patient.

In the context of infectious diseases, biochips provide a rapid and accurate means of monitoring pathogens. The ability to simultaneously test for multiple infectious agents on a single platform is invaluable in epidemiological studies and the surveillance of disease outbreaks. Biochip-based diagnostics contribute to a more comprehensive understanding of infectious diseases, aiding in their containment and management. Biochips play a crucial role in genetic screening, offering a comprehensive analysis of an individual's genetic predispositions. This information is instrumental in genetic counseling, allowing individuals to make informed decisions about their health and potential risks. As genetic screening becomes more integrated into healthcare practices, the demand for biochips in genetic diagnostics and counseling is expected to grow.

#### Key Market Challenges

##### Regulatory Complexity

In Spain's biochip market, one of the most significant challenges is navigating complex regulatory frameworks. Biochips often fall under multiple regulatory categories, including medical devices and diagnostics, creating a labyrinth of compliance requirements. This complexity arises due to the diverse applications of biochip technology, which range from disease diagnostics to genetic screening. As these technologies advance, regulatory bodies must ensure they meet stringent safety, efficacy, and ethical standards, which often leads to slow approval processes. The intricate nature of these regulations can delay the commercialization of new biochip technologies, especially as companies must dedicate considerable resources to comply with both national and European Union (EU) standards. Furthermore, the varying regulatory approaches between regions can complicate international market access, hindering Spain's competitiveness in the global biochip industry. This regulatory burden not only increases costs for manufacturers but also risks stifling innovation by making it more difficult to introduce new, cutting-edge technologies. These challenges require companies to remain adaptable, invest in regulatory expertise, and collaborate closely with regulatory bodies to ensure their products can meet evolving standards and reach the market efficiently.

##### Cost Constraints

Cost constraints present a significant challenge for the Spain Biochip Market. The high production costs associated with biochips,

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

particularly those requiring advanced materials, precision manufacturing, and specialized technologies, limit their widespread adoption. The investment needed for research and development (R&D) to enhance biochip capabilities further adds to the cost burden. These costs are often passed down to end users, such as healthcare providers and research institutions, which can hinder accessibility, especially for smaller or resource-limited entities. Despite the advancements in biochip technology, such as improvements in sensitivity, specificity, and multiplexing capabilities, the price of integrating these technologies remains a barrier. Biochips with microarray and nanotechnology features, for example, offer higher performance but at a premium cost. Additionally, there is competition from alternative diagnostic technologies that are often less expensive or easier to implement, such as PCR-based systems or traditional laboratory testing methods. This makes it more difficult for biochips to gain a foothold in markets where cost-efficiency is a primary concern. Biochip technologies also require substantial infrastructure investments, further elevating the financial strain on the healthcare systems and research institutions adopting them. While large organizations may have the resources to absorb these costs, smaller entities or those in economically constrained regions face significant barriers to implementing biochip solutions. Addressing these cost constraints is essential for ensuring the broader integration of biochips into healthcare and biotechnology sectors across Spain

#### Key Market Trends

##### Advancements in Point-of-Care (POC) Applications

The Spain biochip market is experiencing significant growth due to advancements in point-of-care (POC) applications. These innovations have led to increased demand for biochip technologies such as lab-on-a-chip and microarray systems. The ability of biochips to rapidly perform multiple biological tests on small sample volumes is especially valuable in clinical diagnostics, where quick results are crucial. Their role in drug discovery, genomics, and proteomics further supports this trend. As healthcare systems prioritize fast, accurate diagnostics and personalized treatment, the use of biochips for point-of-care applications becomes more prominent. These biochips are being tailored for applications such as infectious disease detection, offering quick and reliable results that contribute to effective disease management and surveillance.

The miniaturization of biochip technologies is improving their efficiency, making them more accessible for widespread use in diagnostics. This growth is driven by increased investment in healthcare infrastructure and the push for innovations in medical technology. The rising application of biochips in both clinical and research settings, especially in the detection of genetic disorders and cancer, is expected to continue propelling the market forward

##### Expansion of Liquid Biopsy Applications

The Spain biochip market is witnessing significant growth due to the expansion of liquid biopsy applications, particularly in cancer detection and monitoring. Liquid biopsy, a non-invasive technique that analyzes blood samples for biomarkers like circulating tumor DNA (ctDNA), has gained traction for its ability to provide early cancer detection and monitor treatment responses in real-time. This shift towards liquid biopsy aligns with the growing adoption of personalized medicine, as it enables oncologists to tailor treatments based on a patient's genetic profile, enhancing therapeutic outcomes. Spain's increasing focus on biotechnology, supported by investment in healthcare infrastructure, is further driving the demand for biochips. These advancements, especially in technologies like next-generation sequencing (NGS) and polymerase chain reaction (PCR), have improved the accuracy and efficiency of liquid biopsy, positioning it as a key tool in oncology. Additionally, the market benefits from the preference for non-invasive diagnostic options, as liquid biopsy offers a safer alternative to traditional tissue biopsies.

Key applications of liquid biopsy in Spain include the detection and monitoring of breast, lung, and colorectal cancers, along with tracking disease progression and recurrence. The growth of clinical research, coupled with strategic partnerships between healthcare institutions and tech companies, is expected to continue boosting the adoption of liquid biopsy technologies in the country.

#### Segmental Insights

##### Technology Insights

Based on Technology, Microarray technology is poised to dominate the Biochip Market in Spain for several compelling reasons. Firstly, its ability to analyze thousands of genes simultaneously provides a comprehensive and high-throughput approach, significantly accelerating research and diagnostics processes. This efficiency is crucial in the fast-paced landscape of biotechnology. Additionally, Microarray technology offers a cost-effective solution, making it accessible to a broader range of research institutions and companies. Its versatility enables the study of diverse biological samples, enhancing its appeal across

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

various applications, from genomics to personalized medicine. As Spain continues to invest in biotechnological advancements, the scalability, cost-effectiveness, and versatility of Microarray technology position it as the frontrunner in shaping the future of the Biochip Market in the country.

#### Application Insights

Based on Application, Drug discovery and development are set to dominate the application landscape in the Spain Biochip Market due to their pivotal role in advancing pharmaceutical research and innovation. Biochips offer a streamlined platform for studying molecular interactions, identifying potential drug candidates, and assessing their efficacy and safety profiles. Spain's growing emphasis on biomedical research and the increasing need for targeted and personalized therapeutics align perfectly with the capabilities of biochips in expediting drug discovery processes. The high-throughput nature of biochip technology allows researchers to screen a vast number of compounds efficiently, reducing both time and costs associated with drug development. With a keen focus on advancing healthcare solutions, the integration of biochips into drug discovery pipelines positions it as a driving force in shaping the future of the biochip market in Spain.

#### Regional Insights

The Central Region of North Spain is poised to dominate the Spain Biochip Market as the largest market due to a confluence of strategic factors. This region boasts a robust ecosystem of research institutions, biotech companies, and academic centers, fostering a thriving environment for technological advancements. The concentration of top-tier research facilities and a skilled workforce enhances the adoption of biochip technology in various applications, from healthcare to agriculture. Additionally, the Central Region's collaborative approach to interdisciplinary research and development creates synergies that fuel innovation in the biochip sector. The strategic geographical location further facilitates efficient distribution networks, ensuring seamless access to cutting-edge biochip technologies. As a result, the Central Region of North Spain emerges as a powerhouse, driving the growth and dominance of the biochip market in the country.

#### Key Market Players

- Abbott Laboratories, S.A.
- Agilent Technologies Spain, S.L.
- GE HealthCare Technologies Inc. (Spain)
- Bio-Rad Laboratories, S.A.
- Fisher Scientific SL
- bioMerieux Espana S.A.
- HORIBA ABX SAS
- QIAGEN Iberia, S.L.
- Laboratorios Randox S.L.
- PerkinElmer (Spain)

#### Report Scope:

In this report, the Spain Biochip Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

#### □□ Spain Biochip Market, By Technology:

- o Microarray
- o Microfluidics

#### □□ Spain Biochip Market, By Type:

- o DNA Chips
- o Lab-On-a-Chips
- o Protein Chips
- o Others

#### □□ Spain Biochip Market, By Application:

- o Drug Discovery & Development
- o Disease Diagnostics
- o Genomics

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- o Proteomics

- o Others

☐☐Spain Biochip Market, By End User:

- o Hospitals & Diagnostics Centers

- o Academic & Research Institutes

- o Biotechnology & Pharmaceutical Companies

- o Others

☐☐Spain Biochip Market, By Region:

- o Central Region North Spain

- o Aragon & Catalonia

- o Andalusia, Murcia & Valencia

- o Madrid, Extremadura & Castilla

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Spain Biochip Market.

Available Customizations:

Spain Biochip market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

☐☐Detailed analysis and profiling of additional market players (up to five).

## **Table of Contents:**

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validation

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Spain Biochip Market Outlook

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Technology (Microarray, Microfluidics)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.2.2. By Type (DNA Chips, Lab-On-a-Chips, Protein Chips, Others)
- 5.2.3. By Application (Drug Discovery & Development, Disease Diagnostics, Genomics, Proteomics, Others)
- 5.2.4. By End User (Hospitals & Diagnostics Centers, Academic & Research Institutes, Biotechnology & Pharmaceutical Companies, Others)
- 5.2.5. By Region
- 5.2.6. By Company (2023)
- 5.3. Market Map
  - 5.3.1. By Technology
  - 5.3.2. By Type
  - 5.3.3. By Application
  - 5.3.4. By End User
  - 5.3.5. By Region
- 6. Central Region North Spain Biochip Market Outlook
  - 6.1. Market Size & Forecast
    - 6.1.1. By Value
  - 6.2. Market Share & Forecast
    - 6.2.1. By Technology (Microarray, Microfluidics)
    - 6.2.2. By Type (DNA Chips, Lab-On-a-Chips, Protein Chips, Others)
    - 6.2.3. By Application (Drug Discovery & Development, Disease Diagnostics, Genomics, Proteomics, Others)
    - 6.2.4. By End User (Hospitals & Diagnostics Centers, Academic & Research Institutes, Biotechnology & Pharmaceutical Companies, Others)
- 7. Aragon & Catalonia Biochip Market Outlook
  - 7.1. Market Size & Forecast
    - 7.1.1. By Value
  - 7.2. Market Share & Forecast
    - 7.2.1. By Technology (Microarray, Microfluidics)
    - 7.2.2. By Type (DNA Chips, Lab-On-a-Chips, Protein Chips, Others)
    - 7.2.3. By Application (Drug Discovery & Development, Disease Diagnostics, Genomics, Proteomics, Others)
    - 7.2.4. By End User (Hospitals & Diagnostics Centers, Academic & Research Institutes, Biotechnology & Pharmaceutical Companies, Others)
- 8. Andalusia, Murcia & Valencia Biochip Market Outlook
  - 8.1. Market Size & Forecast
    - 8.1.1. By Value
  - 8.2. Market Share & Forecast
    - 8.2.1. By Technology (Microarray, Microfluidics)
    - 8.2.2. By Type (DNA Chips, Lab-On-a-Chips, Protein Chips, Others)
    - 8.2.3. By Application (Drug Discovery & Development, Disease Diagnostics, Genomics, Proteomics, Others)
    - 8.2.4. By End User (Hospitals & Diagnostics Centers, Academic & Research Institutes, Biotechnology & Pharmaceutical Companies, Others)
- 9. Madrid, Extremadura & Castilla Biochip Market Outlook
  - 9.1. Market Size & Forecast
    - 9.1.1. By Value
  - 9.2. Market Share & Forecast
    - 9.2.1. By Technology (Microarray, Microfluidics)
    - 9.2.2. By Type (DNA Chips, Lab-On-a-Chips, Protein Chips, Others)
    - 9.2.3. By Application (Drug Discovery & Development, Disease Diagnostics, Genomics, Proteomics, Others)
    - 9.2.4. By End User (Hospitals & Diagnostics Centers, Academic & Research Institutes, Biotechnology & Pharmaceutical Companies, Others)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Companies, Others)

10. Market Dynamics

10.1. Drivers

10.2. Challenges

11. Market Trends & Developments

11.1. Recent Developments

11.2. Mergers & Acquisitions

11.3. Product Launches

12. Policy & Regulatory Landscape

13. Porter's Five Forces Analysis

13.1. Competition in the Industry

13.2. Potential of New Entrants

13.3. Power of Suppliers

13.4. Power of Customers

13.5. Threat of Substitute Products

14. Spain Economic Profile

15. Competitive Landscape

15.1. Abbott Laboratories, S.A.

15.1.1. Business Overview

15.1.2. Product Offerings

15.1.3. Recent Developments

15.1.4. Financials (As Reported)

15.1.5. Key Personnel

15.1.6. SWOT Analysis

15.2. Agilent Technologies Spain, S.L.

15.3. GE HealthCare Technologies Inc. (Spain)

15.4. Bio-Rad Laboratories, S.A.

15.5. Fisher Scientific SL

15.6. bioMerieux Espana S.A.

15.7. HORIBA ABX SAS

15.8. QIAGEN Iberia, S.L.

15.9. Laboratorios Randox S.L.

15.10. PerkinElmer (Spain)

16. Strategic Recommendations

17. About Us & Disclaimer

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Spain Biochip Market By Technology (Microarray, Microfluidics), By Type (DNA Chips, Lab-On-a-Chips, Protein Chips, Others), By Application (Drug Discovery & Development, Disease Diagnostics, Genomics, Proteomics, Others), By End User (Hospitals & Diagnostics Centers, Academic & Research Institutes, Biotechnology & Pharmaceutical Companies, Others), By Region, Competition Forecast & Opportunities, 2019-2029F**

Market Report | 2024-12-13 | 85 pages | TechSci Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$3500.00
	Multi-User License	\$4500.00
	Custom Research License	\$7000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-10"/>
		Signature	<input type="text"/>